The company said, “Kestra is increasing its FY26 revenue guidance to $88 million, representing growth of 47% compared to FY25. This compares to prior FY26 revenue guidance of $85 million.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KMTS:
- KMTS Earnings this Week: How Will it Perform?
- Kestra Medical’s 2025 Annual Shareholder Meeting Outcomes
- RxSight appoints Raymond Cohen to its board of directors
- Kestra Medical Technologies Ltd.: Balanced Hold Rating Amid Revenue Growth and EBITDA Challenges
- Kestra Medical Technologies Reports Strong Revenue Growth